Skip to main content

Table 2 Bleeding characteristics of the study subjects

From: Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding

Variables Conventional therapy (n = 112) UI-EWD therapy (n = 55) P-value
Location of bleeding, n (%)
Cecum 5 (4.5) 2 (3.6) 0.625
Ascending colon 18 (16.1) 5 (9.1) 0.219
Hepatic flexure 0 (0.0) 4 (7.3) 0.011+
Transverse colon 12 (10.7) 4 (7.3) 0.478
Descending colon 5 (4.5) 1 (1.8) 0.388
Sigmoid colon 13 (11.6) 10 (18.2) 0.247
Rectum 59 (52.7) 29 (52.7) 0.830
Cause of bleeding, n (%)
Diverticular bleeding 13 (11.6) 4 (7.3) 0.204
Radiation proctitis 13 (11.6) 1 (1.8) 0.037+
Angiodysplasia 9 (8.0) 1 (1.8) 0.168+
Ulcer bleeding 34 (30.4) 18 (32.7) 0.756
Post procedure bleeding 31 (27.7) 25 (45.5) 0.147+
Tumor bleeding 12 (10.7) 6 (10.9) 0.970
Size of bleeding site, n (%)
 < 1 cm 71 (63.4) 15 (27.3)  < 0.001
1–4 cm 32 (28.6) 26 (47.3) 0.022
 > 4 cm 9 (8.0) 14 (25.5) 0.002
Forrest classification, n (%)
Ia 2 (1.8) 5 (9.1) 0.040+
Ib 112 (94.6) 50 (90.1) 0.001+
Treatment modality, n (%)
Coagrasper 38 (33.0) 22 (40.0) 0.397
APC 21 (18.8) 5 (9.1) 0.106
Hemoclipping 81 (53.6) 21 (38.2)  < 0.001
EVL 4 (3.6) 0 (0.0) 0.156
UI-EWD only 0 (0.0) 17 (30.9)  
  1. +Fisher exact test
  2. *P-values were calculated using the t-test or Fisher calculated using the of the conventional therapy group and the UI-EWD therapy group